While the precise mechanisms remain to be fully elucidated, these findings provide a strong rationale for co-targeting RBM39 and MGMT to overcome temozolomide resistance in cancers with high MGMT expression, including glioblastoma and neuroendocrine neoplasms. This evidence concerns the gene RBM39 and neuroendocrine neoplasm.